Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

COG to present at Mello 2026

Cambridge, UK, 1 June 2026: Cambridge Cognition Holdings plc (AIM: COG), the neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care, announces that the Company will be presenting at the Mello 2026 investor event.

Rob Baker, CEO, will present on Wednesday, 3 June 2026, at The Clayton Hotel & Conference Centre, Chiswick High Road, London, W4 5RY.  Rob will be joined by other members of the senior leadership team to take investors questions during the day.

The presentation follows a series of recent positive news events including:

·    FY 2025 financial results showing a 73% increase in new sales orders to £12.8m and a 21% increase in the order book £16.5m; 

·    The launch of the professional healthcare and consumer health business with agreements with a major European healthcare provider, and an agreement with venture backed Ivory for the Indian market; and

·    The announcement of a 45,000 participant IRB-approved Brain Health Study with the world's leading smart ring maker OURA.

Rob's presentation titled "Making Brain Health Measurable At Scale" addresses how Cambridge Cognition has built on 30 years of neuroscience and technology development, with its digital touch-screen and voice-based cognitive assessments.  These have been used for decades supporting academic researchers and clinical drug development and are now being taken into the professional healthcare and consumer health & wellness market.  These markets require highly scalable, reliable, consistent and accurate information delivered without administrator bias in near real time to users.

For further information please visit the event website at www.melloevents.com

ENQUIRIES

NOTES TO EDITORS

ABOUT CAMBRIDGE COGNITION

Cambridge Cognition is a neuroscience technology company whose digital cognitive assessments support scientific discovery, accelerate drug development and improve patient care. 

The Company has developed a suite of touchscreen and voice-based cognitive assessments delivered under the CANTAB and Winterlight brands.  These assessments are designed to:

•           require minimal specialist administration

•           deliver objective results in real time or shortly after completion

•           reduce administrator bias

•           support longitudinal monitoring of cognitive function

Assessment results can be presented in formats appropriate for both consumers in home-use settings and healthcare professionals in clinical or research environments. 

CANTAB Pathway™ is Cambridge Cognition's latest scalable cognitive assessment solution, structured as an escalating series of tasks for use in consumer and healthcare settings:

·    CANTAB One - a brief assessment of overall cognitive function

·    CANTAB Insight™ - a three-task battery providing deeper insight across five cognitive sub-domains

·    CANTAB Plus - specialist disease-specific modules for use by appropriately qualified healthcare professionals, covering eight indications including Parkinson's disease, ADHD, multiple sclerosis, Huntington's disease, schizophrenia, depression, and Alzheimer's disease and related dementias

For further information, visit: www.cambridgecognition.com